NIRAPARIB; TSR-042; TSR-022 3000-01-002
Sample Report - Not for Clinical Use
Houssein A. Sater, MD on Twitter: "TsR-022 targets TIM-3 phase I trial results @sitcancer #SITC2017 https://t.co/E9RAIM3dUV" / Twitter
Discovery of TSR-022, a novel, potent anti-TIM-3 therapeutic antibody
g63792mmi052.gif
Discovery of TSR-022, a novel, potent anti-TIM-3 therapeutic antibody
NIRAPARIB; TSR-042; TSR-022 3000-01-002
TSR-022 for Cancer Clinical Trial 2022 | Power
NIRAPARIB; TSR-042; TSR-022 3000-01-002
Current Oncology | Free Full-Text | New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer | HTML
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities | Nature Reviews Drug Discovery
Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials - ScienceDirect
Strategies to overcome resistance to immune checkpoint blockade in lung cancer - Lung Cancer
g63792mmi059.gif
![Top 10 Immunotherapy Clinical Trials [2022 Studies] | Power](https://pwr-og-img.withpower.com/Apply%20to%20this%20Phase%202%20clinical%20trial%20treating%20Hepatocellular%20Carcinoma,%20Carcinoma,%20Hepatocellular,%20Carcinoma:%0A%0ATremelimumab%20immunotherapy%20for%20Hepatocellular%20Carcinoma.png?md=1 "Top 10 Immunotherapy Clinical Trials [2022 Studies] | Power")
Top 10 Immunotherapy Clinical Trials [2022 Studies] | Power
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) | Journal for ImmunoTherapy of Cancer | Full Text
cobolimab (TSR-022) / AnaptysBio, GSK
Trials Listing
Cells | Free Full-Text | Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor | HTML
Tesaro, Inc. 2018 8-K Current report
What's Next for Immune Checkpoint Inhibitors: TIM-3?
New emerging targets in cancer immunotherapy: the role of TIM3 - ESMO Open
Checkpoint inhibitors and their effects on HIV specific T cells and... | Download Scientific Diagram
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer | Clinical Research Trial Listing ( Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult
Frontiers | Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
